Apotex and Emcure Pharmaceuticals’ Heritage subsidiary have agreed to pay a combined $49.1m to settle three longstanding US antitrust suits alleging that both companies engaged in “widespread, long-running” conspiracies to “artificially inflate and manipulate prices, reduce competition and unreasonably restrain access to numerous generic prescription drugs.”
Apotex And Heritage Reach $50m Settlements For US Price-Fixing Claims
Settlements Come Ahead Of First Trial In Connecticut; State AGs ‘Very Confident’
Two more generics manufacturers have reached agreements with 50 US attorneys general settling claims that they artificially inflated and manipulated the prices of generic drugs for nearly a decade.
